TARGET-BASED METHOD FOR HIGH-THROUGHPUT AND SUBCLASS SPECIFIC IgG GLYCAN PROFILING IN HUMAN PLASMA
US-2024353417-A1 · Oct 24, 2024 · US
Optimized Fc variants and methods for their generation
US9714282B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9714282-B2 |
| Application number | US-201414286825-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 23, 2014 |
| Priority date | Sep 26, 2003 |
| Publication date | Jul 25, 2017 |
| Grant date | Jul 25, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
First claim
Opening claim text (preview).
We claim: 1. A protein comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising an amino acid substitution A330R in the Fc region, wherein said Fc variant exhibits decreased binding to FcγRIIIa as compared to the parent Fc polypeptide and wherein numbering is according to the EU index. 2. The protein according to claim 1 , where said protein is an antibody or immunoadhesin. 3. The protein according to claim 2 , where said protein is an antibody. 4. The protein according to claim 2 , where said protein is an immunoadhesin. 5. A nucleic acid encoding a protein according to claim 1 . 6. An expression vector comprising the nucleic acid of claim 5 . 7. A host cell comprising a nucleic acid according to claim 5 . 8. A method of making a protein comprising: a) culturing a host cell according to claim 7 under conditions wherein said protein is produced; and b) purifying said protein.
Assignees
Inventors
Classifications
Decreased effector function due to an Fc-modification · CPC title
Complement-dependent cytotoxicity [CDC] · CPC title
Increased effector function due to an Fc-modification · CPC title
against CD52 · CPC title
against translation products of oncogenes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9714282B2 cover?
- The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
- Who is the assignee on this patent?
- Xencor Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).